SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
Retrieved on:
Monday, January 29, 2024
Mortality, Patient, Leukemia, LAMB, Therapy, MD, FCCP, Infection, Biotechnology, Survival, Fungal infection, COVID, FAAM, Aspergillosis, Division, Immunodeficiency, Conference, Bone marrow, UCLA, Transplant, B♭ (musical note), Doctor of Philosophy, Antimalarial medication, FIDSA, Harbor–UCLA Medical Center, Lung, AAAM, Diabetes, Pharmaceutical industry
In this highly lethal mouse model of mucormycosis, SCY-247 showed very promising in vivo efficacy.
Key Points:
- In this highly lethal mouse model of mucormycosis, SCY-247 showed very promising in vivo efficacy.
- This is comparable to the 40% survival observed in the control group treated with 10 mg/kg of intravenous standard of care of liposomal amphotericin B (LAMB) (p = 0.008 vs. placebo).
- The combination treatment of SCY-247 plus LAMB demonstrated the greatest reduction in fungal burden and was highly statistically significant in both lung and brain tissue (both p
- “These positive data continue to accumulate and define the unique properties of SCY-247, highlighting its potential to be differentiated from currently available antifungals.